The use of aromatase inhibitors for rapid relief of ovarian hyperstimulation symptoms occurring with an in vitro fertilization program
- Authors: Martirosyan Y.O.1, Nazarenko T.A.1, Korneeva I.E.1, Biryukova A.M.1
-
Affiliations:
- Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation
- Issue: No 11 (2020)
- Pages: 232-236
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249271
- DOI: https://doi.org/10.18565/aig.2020.ll.232-236
- ID: 249271
Cite item
Open Access
Access granted
Abstract
Background. Despite the rather low incidence of severe ovarian hyperstimulation syndrome (OHSS) in IVF programs, this complication during its severe course negatively affects the health of young women, requires intensive and long-term treatment, and leads to pregnancy complications. In this connection, the issues of rapid relief of OHSS symptoms are extremely relevant, especially in patients planning to start gonadotoxic therapy immediately after ovarian stimulation and oocyte retrieval. Case report. There are two clinical cases describing and comparing the eff iciency of using aromatase inhibitors and gonadotropin-releasing hormone antagonists (GnRH-ant) for the rapid relief of ovarian hyperstimulation symptoms. Conclusion. The use of aromatase inhibitors versus GnRH-ant after transvaginal puncture contributes to a more rapid relief of the developed symptoms of ovarian hyperstimulation. It should be noted that the developed procedure is more cost effective than the use of GnRH-ant.
Full Text
About the authors
Yana O. Martirosyan
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation
Email: marti-yana@yandex.ru
Junior Researcher at the F. Paulsen SEC for ART
Tatiana A. Nazarenko
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation
Email: t_nazarenko@oparina4.ru
Dr. Med. Sci., professor, Head of the Institute of Reproductive Medicine
Irina E. Korneeva
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian FederationDr. Med. Sci., Head of F. Paulsen SEC for ART
Almina M. Biryukova
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation
Email: alma21@list.ru
MD, Candidate of Medical Sciences, doctor is in charge of clinical work of the Scientific and Educational Center for ART with the Clinical Division named after F. Paulsen
References
- Регистр ВРТ РАРЧ. 2017: Отчет регистра за 2017 г. и ВРТ в России 2017 г. (Доклад президента РАРЧ на XXIX международной конференции РАРЧ «Репродуктивные технологии сегодня и завтра», Ростов-на-Дону).
- Mathur R.S., Tan B.K. British Fertility Society Policy and Practice Committee: prevention of ovarian hyperstimulation syndrome. Hum. Fertil. (Camb). 2014; 17(4): 257-68. https://dx.doi.org/10.3109/14647273.2014.961745.
- Fouda U.M., Sayed A.M., Elshaer H.S., Hammad B.E., Shaban M.M., Elsetohy K.A. et al. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial. J. Ovarian Res. 2016; 9(1): 29. https://dx.doi. org/10.1186/s13048-016-0237-8.
- Tang H., Mourad S., Zhai S.D., Hart R.J. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev. 2016; (11): CD008605. https://dx.doi.org/10.1002/14651858.CD008605.pub3.
- Lainas T.G., Sfontouris I.A., Zorzovilis I.Z., Petsas G.K., Lainas G.T., Kolibianakis E.M. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod. Biomed. Online. 2007; 15(4): 408-12. https://dx.doi.org/10.1016/s1472-6483(10)60366-5.
- Latouche J., Crumeyrolle-Arias M., Jordan D., Kopp N., Augendre-Ferrante B., Cedard L. et al. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology. 1989; 125(3): 1739-41. https://dx.doi.org/ 10.1210/endo-125-3-1739.
- Minaretzis D., Jakubowski M., Mortola J.F., Pavlou S.N. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J. Clin. Endocrinol. Metab. 1995; 80(2): 430-4. https://dx.doi.org/10.1210/ jcem.80.2.7852501.
- Asimakopoulos B., Nikolettos N., Nehls B., Diedrich K., Al-Hasani S., Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil. Steril. 2006; 86(3): 636 41. https://dx.doi.org/10.1016/j.fertnstert.2006.01.046
- Taylor P.D., Hillier S.G., Fraser H.M. Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J. Endocrinol. 2004; 183(1): 1-17. https://dx.doi.org/10.1677/ joe.1.05685.
- Friden B.E., Nilsson L. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding midluteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization. Acta Obstet. Gynecol. Scand. 2005; 84(8): 812-6. https://dx.doi.org/10.1111/j.0001-6349.2005.00730.x.
- Del Canto F., Sierralta W., Kohen P., Munoz A., Strauss J.F., Devoto L. Features of natural and gonadotropin-releasing hormone antagonist-induced corpus luteum regression and effects of in vivo human chorionic gonadotropin. J. Clin. Endocrinol. Metab. 2007; 92(11): 4436-43. https://dx.doi.org/10.1210/ jc.2007-0125.
- Sahin N., Apaydin N., Toz E., Sivrikoz O.N., Genc M., Turan G.A. et al. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Arch. Gynecol. Obstet. 2016; 293(5): 1101-6. https://dx.doi.org/10.1007/s00404-015-3987-4.
- Haas J., Bassil R., Gonen N., Meriano J., Jurisicova A., Casper R.F. The VEGF and PEDF levels in the follicular fluid of patients co- treated with LETROZOLE and gonadotropins during the stimulation cycle. Reprod. Biol. Endocrinol. 2018; 16(1): 54. https://dx.doi.org/10.1186/s12958-018-0367-5.
Supplementary files
